Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.94 USD | +6.37% | +1.83% | -35.67% |
Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
Evolution of the average Target Price on Sage Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Sage Therapeutics, Inc.
Truist Securities | |
TD Cowen | |
Scotiabank | |
Oppenheimer | |
BofA Securities | |
JPMorgan Chase | |
Deutsche Bank Securities | |
RBC Capital Markets | |
Wedbush | |
Stifel Nicolaus | |
Goldman Sachs | |
Morgan Stanley | |
Mizuho Securities | |
HC Wainwright | |
Needham & Co. | |
Canaccord Genuity | |
Jefferies & Co. | |
SVB Securities LLC | |
Guggenheim | |
BMO Capital | |
Loop Capital | |
Citigroup | |
Berenberg Bank | |
SVB Leerink | |
Cowen | |
William Blair & Co. | |
Piper Sandler | |
Raymond James |
EPS Revisions
- Stock Market
- Equities
- SAGE Stock
- Consensus Sage Therapeutics, Inc.